Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations.

Camila Muñoz, Francisco Adasme, Ariela Vergara-Jaque, Jans H. Alzate-Morales, Torsten Kniess, Julio Caballero
February 1, 2012
Learn More
LinkedIn